TD Cowen Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its price objective hoisted by investment analysts at TD Cowen from $100.00 to $120.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price target would suggest a potential upside of 10.14% from the company’s previous close.

MRK has been the subject of a number of other reports. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $82.00 to $130.00 in a report on Thursday, December 18th. Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. Morgan Stanley raised their price objective on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. UBS Group upped their target price on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Citigroup boosted their price target on shares of Merck & Co., Inc. from $95.00 to $110.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Eight research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Hold” and a consensus target price of $114.20.

Merck & Co., Inc. Stock Up 0.1%

Shares of MRK stock traded up $0.12 during trading hours on Tuesday, reaching $108.95. 6,260,866 shares of the stock were exchanged, compared to its average volume of 12,695,740. The business’s fifty day moving average is $102.54 and its two-hundred day moving average is $90.34. The firm has a market capitalization of $270.42 billion, a P/E ratio of 14.38, a P/E/G ratio of 1.18 and a beta of 0.29. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $112.90. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.66 and a quick ratio of 1.44.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.94 EPS for the quarter, missing the consensus estimate of $2.08 by ($0.14). Merck & Co., Inc. had a return on equity of 44.54% and a net margin of 29.63%. As a group, research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the transaction, the executive vice president directly owned 24,578 shares of the company’s stock, valued at approximately $2,054,475.02. The trade was a 25.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of institutional investors have recently added to or reduced their stakes in the business. Legend Financial Advisors Inc. purchased a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $25,000. Darwin Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after acquiring an additional 216 shares during the period. Kilter Group LLC purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth $27,000. Bare Financial Services Inc boosted its position in Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Finally, Barnes Dennig Private Wealth Management LLC lifted its stake in Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after buying an additional 266 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Five‑year Phase 2b melanoma vaccine data show a sustained ~49% reduction in risk of recurrence or death when Merck’s KEYTRUDA is combined with Moderna’s individualized mRNA therapy — a major clinical win that strengthens MRK’s oncology franchise and supports future clinical programs and commercial upside. Moderna, Merck’s skin cancer vaccine shows sustained benefit after five years
• Positive Sentiment: Pipeline/strategic outlook pieces highlight MRK as positioned for a breakout after recent M&A and an expanding oncology program — commentary that can support multiple analyst upgrades and higher price targets. Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion
• Positive Sentiment: Wells Fargo reaffirmed a Buy on MRK, which can reinforce investor confidence and provide support for the shares amid mixed headlines. Wells Fargo Reaffirms Their Buy Rating on Merck & Company (MRK)
• Neutral Sentiment: Market pieces position MRK as a long‑term dividend/blue‑chip holding (“forever stock”), which supports buy‑and‑hold demand but is less likely to drive short‑term moves. 3 “Forever Stocks” to Hold When the Market Won’t Sit Still (MRK)
• Neutral Sentiment: Valuation/analysis articles weigh whether recent share strength already prices in MRK’s long‑term value — useful context for investors but ambiguous for immediate direction. Is Merck (MRK) Pricing Reflect Long Term Value After Recent Share Price Strength
• Negative Sentiment: Zacks flags sharp Gardasil sales declines in China and Japan, which could pressure Q4 revenues and near‑term guidance — a concrete downside risk for MRK’s top line and market reaction. Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?
• Negative Sentiment: Public filing: Rep. Julie Johnson sold MRK shares — a small potential sentiment headwind (typically limited impact unless part of a larger trend). Rep. Julie Johnson Sells Merck & Co., Inc. (NYSE:MRK) Shares

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.